Skip to content

Study · Not a test of the peptide alone · 2026

26 results

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

Ko A, Chang YC, Bahar F, Wang TH, Xanthavanij N, Yu CC, Hsieh RJ, See XY, Lo SW, Song J, Hsia YP, Chiang CH, Xu X, Lin S, Chiang CH

Annals of internal medicine9 Dec 2025Cited by 24 (Europe PMC)

PMID41359966 (opens in a new tab)DOI10.7326/annals-25-02237 (opens in a new tab)PepBankPUB-41359966
Publisher pagePubMedAsk about this study
Jump to 26 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study26

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone26

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) probably had little or no effect on thyroid cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide probably had little or no effect on thyroid cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeThyroid cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, thyroid cancer
    1.37 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    GLP-1RAs probably have little or no effect on risk for thyroid cancer (OR, 1.37 [95% CI, 0.82 to 2.31]; 1 fewer to 9 more cases per 10 000 patients treated)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) probably had little or no effect on thyroid cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide probably had little or no effect on thyroid cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeThyroid cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, thyroid cancer
    1.37 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    GLP-1RAs probably have little or no effect on risk for thyroid cancer (OR, 1.37 [95% CI, 0.82 to 2.31]; 1 fewer to 9 more cases per 10 000 patients treated)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) probably had little or no effect on pancreatic cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide probably had little or no effect on pancreatic cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreatic cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, pancreatic cancer
    0.84 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    pancreatic cancer (OR, 0.84 [CI, 0.53 to 1.35]; 9 fewer to 6 more per 10 000)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) probably had little or no effect on pancreatic cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide probably had little or no effect on pancreatic cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changePancreatic cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, pancreatic cancer
    0.84 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    pancreatic cancer (OR, 0.84 [CI, 0.53 to 1.35]; 9 fewer to 6 more per 10 000)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) probably had little or no effect on breast cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide probably had little or no effect on breast cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeBreast cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, breast cancer
    0.95 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    breast cancer (OR, 0.95 [CI, 0.60 to 1.49]; 10 fewer to 12 more per 10 000)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) probably had little or no effect on breast cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide probably had little or no effect on breast cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeBreast cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, breast cancer
    0.95 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    breast cancer (OR, 0.95 [CI, 0.60 to 1.49]; 10 fewer to 12 more per 10 000)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  7. 07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) probably had little or no effect on kidney cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide probably had little or no effect on kidney cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeKidney cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, kidney cancer
    1.12 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    kidney cancer (OR, 1.12 [CI, 0.78 to 1.60]; 5 fewer to 13 more per 10 000)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) probably had little or no effect on kidney cancer risk (moderate certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide probably had little or no effect on kidney cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeKidney cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Measurements

    Odds ratio, kidney cancer
    1.12 OR
    pooled GLP-1RAs

    Source sentences

    Summary
    kidney cancer (OR, 1.12 [CI, 0.78 to 1.60]; 5 fewer to 13 more per 10 000)
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  9. 09HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on colorectal cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on colorectal cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeColorectal cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  10. 10HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on colorectal cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on colorectal cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeColorectal cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  11. 11HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on esophageal cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on esophageal cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeEsophageal cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  12. 12HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on esophageal cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on esophageal cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeEsophageal cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  13. 13HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on liver cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on liver cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeLiver cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  14. 14HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on liver cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on liver cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeLiver cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  15. 15HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on gallbladder cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on gallbladder cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeGallbladder cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  16. 16HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on gallbladder cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on gallbladder cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeGallbladder cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  17. 17HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on ovarian cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on ovarian cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeOvarian cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  18. 18HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on ovarian cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on ovarian cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeOvarian cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  19. 19HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on endometrial cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on endometrial cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeEndometrial cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  20. 20HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on endometrial cancer risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on endometrial cancer risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeEndometrial cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  21. 21HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on multiple myeloma risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on multiple myeloma risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeMultiple myeloma risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  22. 22HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on multiple myeloma risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on multiple myeloma risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMultiple myeloma risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  23. 23HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including semaglutide) may have little or no effect on meningioma risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 drugs including semaglutide may have little or no effect on meningioma risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeMeningioma risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  24. 24HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) may have little or no effect on meningioma risk (low certainty).

    In plain wordsIn pooled placebo-controlled trials, GLP-1 and dual agonist drugs including tirzepatide may have little or no effect on meningioma risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMeningioma risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty).
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  25. 25HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, the effect of pooled GLP-1 receptor agonists and dual agonists (including semaglutide) on gastric cancer risk was very uncertain.

    In plain wordsIn pooled placebo-controlled trials, the effect of GLP-1 drugs including semaglutide on gastric cancer risk was very uncertain.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGastric cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    The effect on gastric cancer is very uncertain.
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  26. 26HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In randomized placebo-controlled trials, the effect of pooled GLP-1 receptor agonists and dual agonists (including tirzepatide) on gastric cancer risk was very uncertain.

    In plain wordsIn pooled placebo-controlled trials, the effect of GLP-1 and dual agonist drugs including tirzepatide on gastric cancer risk was very uncertain.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedGastric cancer risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cancer risk · Cancer

    Source sentences

    Summary
    The effect on gastric cancer is very uncertain.
    2 context sentences
    Summary · context
    Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma.
    Summary · context
    The review included 48 trials involving 94 245 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.